Blood and tissue markers could forecast esophageal cancer return
NCT ID NCT07702253
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study examines whether certain proteins and immune signals in the blood and tumor tissue can predict if esophageal squamous cell carcinoma will come back after treatment. Researchers will collect blood and biopsy samples from 120 adults at diagnosis and during early treatment. By mapping how the immune system interacts with the tumor, they aim to develop a way to identify patients at higher risk of recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could lead to a blood test that helps predict which esophageal cancer patients are at higher risk of recurrence, guiding more personalized treatment decisions.
- What could go wrong
- This is an observational study, not a treatment trial, so it will not directly improve outcomes. The findings may not translate into a reliable clinical test without further validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Surgery, Faculty of Medicine, the Chinese University of Hong Kong
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
- Could smarter surgery spare lymph nodes in esophageal cancer?
- Timing of local therapy may boost immunotherapy in Hard-to-Treat esophageal cancer